期刊文献+

HR-HPV载量联合细胞免疫指标预测宫颈癌变进程 被引量:14

Predicting progression of cervical cancer by high risk human papillomavirus load and cellular immunologic indexes
原文传递
导出
摘要 目的比较高危型人乳头状瘤病毒载量(HR-HPV DNA)、CD4^+CD25^+Foxp3^+调节性T细胞(Treg)、T细胞亚群在不同宫颈局部微环境的表达差异,探讨它们预测宫颈癌变进程的可能性和意义。方法将339例HR-HPV持续感染者分为宫颈上皮内瘤变(CIN)和宫颈癌两大组,采用PCR荧光法检测宫颈分泌物HPV-DNA,应用流式细胞仪CD4^+CD25^+Foxp3^+设门和CD45/SSC设门方法分别对宫颈刷检物中的CD4^+CD25^+Treg细胞和CD3^+、CD4^+、CD8^+T细胞相对计数,对数据资料进行单因素方差和多因素Logistic回归统计学分析,筛选宫颈癌预测指标,评估其价值。结果单因素方差分析显示,HR-HPV DNA(X_1)、CD4^+CD25^+Foxp3^+Treg(X_2)、CD3^+(X_3)、CD4^+(X_4)、CD8^+(X_5)在CIN和宫颈癌组均存在差异(均P<0.05),可作为预测宫颈癌变的危险因素,而多因素Logistic回归分析显示,HR-HPV DNA、CD3^+被回归方程剔除,提示CD4^+CD25^+Foxp3^+Treg、CD4^+、CD8^+与宫颈癌发生有关,由此建立回归方程Logit(P)=-16.201^+0.800 X_2+0.687X4-0.665X_5,依回归系数,预测宫颈癌变的密切程度依次为CD4^+CD25^+Foxp3^+Treg>CD4^+>CD8^+。回归模型拟合优度检验Nagelkerke R^2=0.858,对CIN的预判率为94.4%,宫颈癌的预判率为96.0%,总的正判率为95.0%,提示拟合效果好,预测准确度高。结论基于预测宫颈癌变的回归模型,HR-HPV DNA不是预测宫颈癌变的良好指标,可能与HPV的感染状态有更密切的关联,从CIN到宫颈癌,持续感染HR-HPV的宫颈局部微环境免疫细胞表达量不同,在宫颈癌变进程中发挥的作用也不相同,局部免疫失衡造成的宫颈免疫抑制微环境是宫颈癌变的关键环节。 Objective To compare the difference among high risk human papillomavirus load(HR-HPV DNA), CD4^+CD25^+Foxp3^+regulatory T cells(Treg), and T cell subsets in the local microenvironments of cervix, then to discuss the possibility and significance of their predictions of cervical carcinogenesis. Methods A total of 339 cases with HR-HPV persistent infection were divided into two groups: a cervical intraepithelial neoplasia(CIN) group and a cervical cancer group.HPV-DNA from cervical secretion was detected by PCR fluorescence. The relative cell numbers of Treg and CD3^+, CD4^+, CD8^+from cervical brush samples were determine by flow cytometry with the CD4^+CD25^+Foxp3^+and CD45/SSC gating methods respectively. The single factor variance and multivariate logistic regression were used to analyze the data, then the predictors of cervical cancer were screened and their values were evaluated. Results The single factor variance analysis showed that HR-HPV DNA(X1), CD4^+CD25^+Foxp3^+Treg(X2), CD3^+(X3), CD4^+(X4), and CD8^+(X5) were significantly different between the CIN group and cervical cancer group(P〈0.05), and they could be used as predictors of cervical cancer. However, the logistic regression analysis showed that HR-HPV DNA and CD3^+were eliminated by the regression equation, suggesting that CD4^+CD25^+Foxp3^+, CD4^+and CD8^+were associated with cervical cancer. The regression equation was established: Logit(P)=-16.201-+0.800 X2+0.687 X4-0.665 X5. The degree of cervical cancer prediction was CD4^+CD25^+Foxp3^+TregCD4^+〉CD8^+. The goodness of fit test was Nagelkerke R^2= 0.858, the prediction rate for CIN was 94.4%, the prediction rate of cervical cancer was 96.0%, and the total positive rate was 95.0%, indicating that the fitting effect was good and the prediction accuracy was high.Conclusions HR-HPV DNA is not a good predictor of cervical cancer based on the regression model for predicting cervical cancer, and it may be more closely related to the infection of HPV. From CIN to cervical cancer, the expression of immune cells in local microenvironment of cervix with persistent infection of HR-HPV is different, and their roles in the process of cervical cancer are not the same. The immunosuppressive microenvironment caused by local immune imbalance is the key link of cervical cancer.
作者 余杨 付艳丽 邹晶晶 何利珍 孙翔 YU Yang, FU Yanli, ZOU Jingjing, HE Lizhen, SUN Xiang(Department of Laboratory, First Affiliated Hospital of Henan Polytechnic University, Jiaozuo Second People 's Hospital of Henan Province, Jiaozuo, Henan 454100, Chin)
出处 《中国热带医学》 CAS 2018年第3期212-216,共5页 China Tropical Medicine
基金 河南省医学科技攻关项目(No.201702356)
关键词 宫颈癌变 CD4^+CD25^+FOXP3^+调节性T细胞 高危型人乳头状瘤病毒载量 T淋巴细胞亚群 免疫微环境 预测模型 cervical carcinogenesis CD4^+ CD25^+Foxp3^+Treg cell high risk human papillomavirus load T lymphocyte subset immune microenvironment prediction model
  • 相关文献

参考文献7

二级参考文献65

  • 1Guo M ,Sneige N ,Silva EG ,et a|. Distribution and viral load of eight oncogenic types of human papillomavirus(HPV) and HPV 16 integra- tion status in cervical intraepithelial neoplasia and carcinoma [ J ]. Mod Patho1,2007,20 (2) :256 - 266.
  • 2Christothea CW, Stuart IC, Sally R, et al. Is human papillomavirus vi- ral load a clinically useful predictive marker:a longitudinal study[ J]. Cancer Epidemiol Biomarkers Prey,2010,19 ( 3 ) : 832 - 837.
  • 3Xue Y,Bellanger S,Zhang W,et al. HPV16 E2 Is an immediate early marker of viral infection, preceding E7 expression in precursor struc- tures of cervical carcinoma [ J ]. Cancer Res, 2010, 70 ( 13 ) : 5316 - 5325.
  • 4Cheung JL, Lo KW, Cheung TH, et al. Viral load, E 2 gene disruption status, and lineage of human papillomavirus type 16 infection in cervi- cal neoplasia [ J ]. J Infect Dis,2006,194 ( 12 ) : 1706 - 1712.
  • 5Saunier M, Monnier-Benoit S, Mauny F, et al. Analysis of human pap- illomavirus type 16 (HPV16)DNA load and physical state for identifi- cation of HPV16-infected women with high-grade lesions or cervical carcinoma[ J]. J Clin Microbio1,2008,46( 11 ) :3678 -3685.
  • 6Aqorastos T, Chatzistamatiou K, Katsamaqkas T, et al. Primary Screen- ing for Cervical Cancer Based on High-Risk Human Papillomavirus (HPV) Detection and HPV 16 and HPV 18 Genotyping, in Comparison to Cytology[J]. PloS One, 2015,10(3):0119755.
  • 7Kabekkodu SP, Bhat S, Pandey D, et al. Prevalence of Human Papillo- mavirus Types and Phylogenetic Analysis of HPV- 16 L1 Variants from Southern India[J]. Asian Pac J Cancer Prev, 2015, 16(5):2073- 2080.
  • 8Futai M, Watanabe J, Jobo T, et al. Clinical Significance of Human Pap- illomavirus Genotype by Linear Array Assay in Japanese Women With Uterine Cervical Lesions and Type 16 Physical Status by In Situ Hy- bridization[J]. Int J Gynecol Cancer, 2009, 19(8):1396-1401.
  • 9Karunm'atne K, Ihalagama H, Rohitha S, et al. Human papillomavirus prevalence and type-distribution in women with cervical lesions: a cross-sectional study in Sri Lanka[J]. BMC Cancer,2014,14:116.
  • 10Mitz A, Price H, Shahmanesh M, et al. Systematic review and meta- analysis of L1- VLP- based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure[J]. PloS One, 2014, 9(3): 90348.

共引文献126

同被引文献131

引证文献14

二级引证文献93

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部